| Total N | 300 |
| Mean Age | 67.5 (±11.1) |
| Females | 232 (77.3%) |
| Seropositive | 111 (53.6%) |
| Received 2nd Vaccine | 140 (46.7%) |
| Medications | |
| MTX (mean dose=17.1mg/week) | 118 (39.3%) |
| Prednisone (mean dose=4.69 mg/day) | 81(27.0%) |
| Tofacitinib | 44 (14.7%) |
| TNF inhibitors * | 91 (30.3%) |
| Other biologic therapy ** | 47 (15.7%) |
| Other immunosuppressants*** | 37 (12.3%) |
| Diagnosis | |
| RA | 207 (69.0%) |
| Psoriatic Arthritis | 21 (7.00%) |
| Vasculitis | 12 (4.00%) |
| SLE | 11 (3.67%) |
| CTD/MCTD | 7 (2.33%) |
| Other **** | 42 (14.0%) |
* Adalimumab, Certolizumab pegol, Etanercept, Golimumab, Infliximab
** Abatacept, Tocilizumab, Rituximab, Sarilumab
***Azathioprine, Cyclophosphamide, Mycophenolic acid, Leflunomide
****Other includes: Gout, Scleroderma, Sjogren’s, Ankylosing spondylitis, Dermatomyositis